Rex Energy Corporation (REXX) saw its value decrease by -7.3% as the stock dropped $-0.05 to finish the day at a closing price of $0.69. The stock was lighter in trading and has fluctuated between $0.23-$2.43 per share for the past year. The shares, which traded within a range of $0.675 to $0.75 during the day, are up by 96% in the past three months and up by 12.46% over the past six months. It is currently trading -2.97% below its 20 day moving average and 15.6% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $0 a share over the next twelve months. The current relative strength index (RSI) reading is 53.92.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Rex Energy Corporation operates as an independent oil, natural gas liquid, and natural gas company in the Appalachian and Illinois basins in the United States. The company focuses on the Marcellus Shale, Utica Shale, and Burkett Shale drilling and exploration activities in the Appalachian Basin, as well as on developmental oil drilling on its properties in the Illinois Basins. As of December 31, 2015, it had estimated proved reserves of 680.4 billion cubic feet equivalent; and owned interests in approximately 1,819 oil and natural gas wells. Rex Energy Corporation was founded in 2007 and is headquartered in State College, Pennsylvania.
RSP Permian, Inc. (RSPP) shares were up in last trading by 1.39% to $43.7. It experienced higher than average volume on day. The stock increased in value by almost 7.58% over the past week and grew 1.96% in the past month. It is currently trading 0.57% above its 50 day moving average and 13.64% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -6.86% decrease in value from its one year high of $46.92. The RSI indicator value of 58.54, lead us to believe that it is a hold for now.
RSP Permian, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, development, and production of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin of West Texas. It owns interest in contiguous acreage blocks in the core of the Midland Basin, a sub-basin of the Permian Basin, primarily in the adjacent counties of Midland, Martin, Andrews, Dawson, Ector, and Glasscock. RSP Permian, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Merrimack Pharmaceuticals, Inc. (MACK) traded within a range of $3.17 to $3.28 after opening the day at $3.22. The company has seen its stock decrease in value by -20.59% so far this year. The stock was up close to 0.31% on light volume in last trading session and closed at $3.24 per share. After the recent gain, the stock is currently holding -64.08% below its 52 week high of $9.02 and 14.49% above its 12-month low of $2.83. The shares are down by over -51.13% in the last three months, and the RSI indicator value of 41.62 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.